Gene therapy approach in prostate cancer cells using an active Wnt signal - 21/03/08
Corresponding author. Integrated Cancer Prevention Center, Tel Aviv Medical Center, 6 Weizmann Street, Tel Aviv 64239, Israel. Tel.: +972 3 6974968; fax: +972 3 6950339.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Background |
Functional activation of β-catenin/T-cell factor (Tcf) signaling plays an important role in the early events of carcinogenesis. In past recent years accumulated evidence has demonstrated a significant role for the Wnt pathway in the development and progression of human prostate cancer. The objective of the current study was to use a gene-targeting approach to selectively kill human prostate cancer cells with activated β-catenin/Tcf signaling.
Methods |
A recombinant adenovirus that carries a lethal gene (PUMA) under the control of a β-catenin/T-cell factor (Tcf)-responsive promoter (Ad-TOP-PUMA), was used to selectively target human prostate cancer cells (PC-3) in which the β-catenin/Tcf pathway is activated, and compared its killing efficiency in cancer cells in which this pathway is inactive (DU145 cells). Ad-FOP-PUMA, carrying a mutant Tcf binding site, was used as a control virus. Cell viability was measured by methylene blue assay, and the level of β-catenin/Tcf activity was measured by luciferase assay.
Results |
The Ad-TOP-PUMA adenovirus inhibited PC-3 cell growth in a dose and time-dependent fashion, but did not had any effect on DU145 cell growth.
Conclusions |
Selective targeting of prostate cancer cells with the activated β-catenin pathway may be a novel and effective therapy in prostate cancer.
Le texte complet de cet article est disponible en PDF.Keywords : β-Catenin, Prostate cancer, Gene therapy
Plan
Vol 61 - N° 9
P. 527-530 - octobre 2007 Retour au numéro
Article précédent
- Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma
- D.C.W. Lee, D.T.T. Chua, W.I. Wei, J.S.T. Sham, A.S.Y. Lau
- Paclitaxel albumin-bound particles (abraxane™) in combination with bevacizumab with or without gemcitabine: Early experience at the University of Miami/Braman Family Breast Cancer Institute
- Christopher Lobo, Gilberto Lopes, Orlando Silva, Stefan Gluck
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?